Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A study demonstrated that viral immune evasion enabled breakthrough infections of COVID-19 in patients with lung cancer, highlighting the importance of effective monitoring mechanisms, such as anti-N serology, to track infection rates in specific vulnerable populations. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

Login